Immunization with electroporation enhances the protective effect of a DNA vaccine candidate expressing prME antigen against dengue virus serotype 2 infection

Chen, Hui; Zheng, Xiaoyan; Wang, Ran; Gao, Na; Sheng, Ziyang; Fan, Dongying; Feng, Kaihao; Liao, Xianzheng; An, Jing

doi:10.1016/j.clim.2016.08.021

Cited by 17 publications

(18 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After DV2 challenge, only the B-EP group exhibited protection compared with the B-IM and control groups. This result was consistent with our recent study, in which the pVAX1-D2ME via IM failed to provide full protection (Chen et al, 2016). The symptoms were not aggravated in the mice immunized with the bivalent vaccine via EP after challenge with DV1 or DV2, and 33% of body weight loss after DV2 challenge was similar with those in the monovalent DV2 vaccine-immunized mice (Chen et al, 2016), meaning no ADE occurred.…”

Section: Discussionsupporting

confidence: 93%

“…This result was consistent with our recent study, in which the pVAX1-D2ME via IM failed to provide full protection (Chen et al, 2016). The symptoms were not aggravated in the mice immunized with the bivalent vaccine via EP after challenge with DV1 or DV2, and 33% of body weight loss after DV2 challenge was similar with those in the monovalent DV2 vaccine-immunized mice (Chen et al, 2016), meaning no ADE occurred. In combination with the results in our previous study, the effectiveness of the pVAX1-D1ME vaccine candidate is mainly attributed to the suitable immunogen and EP delivery system.…”

Section: Discussionsupporting

confidence: 93%

“…In Australia, a growth hormone-releasing hormone plasmid delivered by EP has been approved in the treatment of pigs (Person et al, 2008). In our recent studies, the DNA vaccine candidates inoculated using EP showed enhanced expression of the antigen in local sites, strong immune response and protective efficacy in mice, rabbits and pigs (Chen et al, 2016; Sheng et al, 2016). Thus, in the present study, we constructed the DNA vaccine candidate pVAX1-D1ME and explored in vivo EP for gene delivery in comparison with traditional IM injection in mice.…”

Section: Discussionmentioning

confidence: 99%

“…Two weeks after the last immunization, the mice were challenged with 50 LD 50 of DV1 (2 × 10 7 PFU) or 30 LD 50 of DV2 (600 PFU) intracerebrally (Chen et al, 2016). Body weight, clinical signs, and mortality were monitored daily for 30 days.…”

Section: Methodsmentioning

confidence: 99%

“…Recently, to translate the DNA vaccine candidates for further clinical application, the plasmids were reconstructed using pVAX1, a unique US FDA-approved vector for developing DNA vaccines; it was confirmed that the DNA vaccine candidate pVAX1-D2ME containing the prM and E genes of DV2 could protect mice from lethal DV2 infection and induce an effective specific antibody response in rabbits (Chen et al, 2016). These findings establish an important foundation for further researching a DV1 vaccine.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Effective Protection Induced by a Monovalent DNA Vaccine against Dengue Virus (DV) Serotype 1 and a Bivalent DNA Vaccine against DV1 and DV2 in Mice

Zheng

Chen

Wang

et al. 2017

Front. Cell. Infect. Microbiol.

Self Cite

View full text Add to dashboard Cite

Dengue virus (DV) is the causal pathogen of dengue fever, which is one of the most rapidly spread mosquito-borne disease worldwide and has become a severe public health problem. Currently, there is no specific treatment for dengue; thus, a vaccine would be an effective countermeasure to reduce the morbidity and mortality. Although, the chimeric Yellow fever dengue tetravalent vaccine has been approved in some countries, it is still necessary to develop safer, more effective, and less costly vaccines. In this study, a DNA vaccine candidate pVAX1-D1ME expressing the prME protein of DV1 was inoculated in BALB/c mice via intramuscular injection or electroporation, and the immunogenicity and protection were evaluated. Compared with traditional intramuscular injection, administration with 50 μg pVAX1-D1ME via electroporation with three immunizations induced persistent humoral and cellular immune responses and effectively protected mice against lethal DV1 challenge. In addition, immunization with a bivalent vaccine consisting of pVAX1-D1ME and pVAX1-D2ME via electroporation generated a balanced IgG response and neutralizing antibodies against DV1 and DV2 and could protect mice from lethal challenge with DV1 and DV2. This study sheds new light on developing a dengue tetravalent DNA vaccine.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Discussionsupporting

confidence: 93%

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Effective Protection Induced by a Monovalent DNA Vaccine against Dengue Virus (DV) Serotype 1 and a Bivalent DNA Vaccine against DV1 and DV2 in Mice

Zheng

Chen

Wang

et al. 2017

Front. Cell. Infect. Microbiol.

Self Cite

View full text Add to dashboard Cite

show abstract

Electroporation-Mediated Immunization of a Candidate DNA Vaccine Expressing Dengue Virus Serotype 4 prM-E Antigen Confers Long-Term Protection in Mice

et al. 2019

Self Cite

View full text Add to dashboard Cite

Dengue fever, caused by dengue viruses (DENVs), is a widespread mosquito-borne zoonotic disease; however, there is no available anti-dengue vaccine for worldwide use. In the current study, a DNA vaccine candidate (pV-D4ME) expressing prM-E protein of DENV serotype 4 (DENV-4) was constructed, and its immunogenicity and protection were evaluated in immunocompetent BALB/c mice. The pV-D4ME candidate vaccine induced effective humoral and cellular immunity of mice against DENV-4 in vivo when administered both at 50 lg and 5 lg through electroporation. Two weeks after receiving three immunizations, both doses of pV-D4ME DNA were shown to confer effective protection against lethal DENV-4 challenge. Notably, at 6 months after the three immunizations, 50 lg, but not 5 lg, of pV-D4ME could provide stable protection (100% survival rate) against DENV-4 lethal challenge without any obvious clinical signs. These results suggest that immunization with 50 lg pV-D4ME through electroporation could confer effective and long-term protection against DENV-4, offering a promising approach for development of a novel DNA vaccine against DENVs.

show abstract

Peptides P4 and P7 derived from E protein inhibit entry of dengue virus serotype 2 via interacting with β3 integrin

Cui

Fan

et al. 2018

Antiviral Research

View full text Add to dashboard Cite

Immunization with electroporation enhances the protective effect of a DNA vaccine candidate expressing prME antigen against dengue virus serotype 2 infection

Cited by 17 publications

References 55 publications

Effective Protection Induced by a Monovalent DNA Vaccine against Dengue Virus (DV) Serotype 1 and a Bivalent DNA Vaccine against DV1 and DV2 in Mice

Effective Protection Induced by a Monovalent DNA Vaccine against Dengue Virus (DV) Serotype 1 and a Bivalent DNA Vaccine against DV1 and DV2 in Mice

Electroporation-Mediated Immunization of a Candidate DNA Vaccine Expressing Dengue Virus Serotype 4 prM-E Antigen Confers Long-Term Protection in Mice

Peptides P4 and P7 derived from E protein inhibit entry of dengue virus serotype 2 via interacting with β3 integrin

Contact Info

Product

Resources

About